It groups patients by diagnostic category for analysis and provides several key measurements of resource utilization (e.g.average length of stay vs published national averages).
This is a numerical coding scheme of over 13,000 diagnoses and 5,000 procedures.
Note: "CC" signifies a significant complication or comorbidity. Source: Med PAR, FY 2008 (early release for discharges during first nine months), Short-term acute care hospitals only.
CMS indicated that “Our clinical advisors agree that until there is a way to specifically identify percutaneous ECMO in the claims data to enable further analysis, a proposal at this time is not warranted.” It just so happens that the FY 2019 ICD-10-PCS procedure code files include new ICD-10-PCS procedure codes identifying percutaneous ECMO procedures.
Additionally, the current code for ECMO procedures (ICD-10-PCS code 5A15223) has been revised. procedure, CMS reviewed the predecessor procedure code assignments.
CMS maintained their proposal to not create a new Pre-MDC MS-DRG for procedures involving the Civa Sheet® technology for FY 2019.
Laryngectomy Pre-MDC MS-DRGs 11, 12 and 13 (Tracheostomy for Face, Mouth and Neck Diagnoses with MCC, with CC, and without CC/MCC, respectively) Current logic for case assignment to MS-DRGs 11, 12 and 13: Chimeric Antigen Receptor (CAR) T-Cell Therapy “Chimeric Antigen Receptor (CAR) T-cell therapy is a cell-based gene therapy in which T-cells are genetically engineered to express a chimeric antigen receptor that will bind to a certain protein on a patient’s cancerous cells.Commenters agreed with CMS that available claims data doesn’t reflect recent advice published in for ICD-10-CM/PCS regarding the coding of procedures involving external heart assist devices or recent changes to ICD-10-PCS codes for these procedures.At this time CMS is maintaining the current structure of Pre-MDC MS-DRGs 001 and 002 for FY 2019 and plans to continue to analyze claims data for consideration of future modifications.The hospital's payment rate is defined by Federal regulations and is updated annually to reflect inflation, technical adjustments, and budgetary constraints.There are separate rate calculations for large urban hospitals and other hospitals.The CAR T-cells are then administered to the patient to attack certain cancerous cells and the individual is observed for potential serious side effects that would require medical intervention.” Two CAR T-cell therapy drugs received FDA approval in 2017 (KYMRIAH™ manufactured by Novartis Pharmaceuticals Corporation and YESCARTA™ manufactured by Kite Pharma, Inc.).Current ICD-10-PCS procedures codes involving the CAR T-cell therapy drugs includes: Both codes became effective October 1, 2017.Therefore, CMS finalized their proposals to: In addition to a new MS-DRG assignment and MS-DRG title revision, both manufacturers of CAR T-cell therapy submitted applications and were approved for new technology add-on payments for FY 2019.MDC 1: Diseases and Disorders of the Nervous System Epilepsy with Neurostimulator In the FY 2018 IPPS/LTCH PPS Final Rule, CMS finalized their proposal “to reassign all cases reporting a principal diagnosis of epilepsy…The Medicare Inpatient Prospective Payment System was first introduced in 1985 and the patient classification system was totally revised for the federal fiscal 2008 beginning October 1, 2007.This revision was designed to better adjust for severity of illness.